Posted 7 July 2021
An emerging biotech with a substantial pipeline
Imunexus is an Australian antibody enhancement company which discovers, develops and commercialises therapies to treat oncological, immunological and other serious diseases. Founded in 2014, it is now actively preparing for an IPO.
Your brief is to work collaboratively with the board, staff and advisors to expedite the listing and to ensure long term prosperity through the implementation of the company’s multi-faceted strategy.
An experienced leader and manager in an emerging life sciences company, you are familiar with ASX compliance issues and you have a record or success in technology licensing and partnership development. Adept in investor relations, you are financially literate, energetic and capable of dealing with ambiguity.
For more information you can contact Jeremy Wurm on 0419 529 525 or Lesley Lightfoot on 0458 543 485.